NEKTAR THERAPEUTICS
For the period ended Mar 31, 2024. Filed May 10, 2024.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2024 · Filed May 10, 2024
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Item 5. Other Information
On May 8, 2024, Myriam J. Curet, M.D., F.A.C.S, a member of the Board of Directors (the “Board”) of the Company, decided to resign from her Board service and provided notice of her resignation from the Board as a Class I director and all committees thereof effective at the conclusion of the Company’s 2024 annual meeting of stockholders taking place on June 5, 2024; her resignation was not the result of any disagreement with the Company on any matter relating to its operations, policies or practices. The Company thanks Dr. Curet for her approximately five years of service as a director and wishes her well in her future endeavors.
Rule 10b5-1 Trading Arrangements
During the three months ended March 31, 2024, our directors and officers adopted or terminated the contracts, instructions or written plans for the purchase or sale of our securities set forth in the table below.
| Type of Trading Arrangement | |||||||
| Name | Title | Action | Adoption / Termination Date | Rule 10b5-1(1) | Non -Rule 10b5-1(2) | Total Shares of Common Stock to be Sold | Expiration Date |
|---|---|---|---|---|---|---|---|
| Robert Chess | Director | Adopt | March 14, 2024 | X | up to 19,500 | July 15, 2024 | |
(1) Contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c) under the Exchange Act.
(2) “Non-Rule 10b5-1 trading arrangement” as defined in Item 408(c) of Regulation S-K under the Exchange Act.
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.